{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:49:52Z","timestamp":1773323392787,"version":"3.50.1"},"reference-count":32,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"3","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["Biomed."],"abstract":"<jats:p>Introducci\u00f3n. La nesfatina-1 es la prote\u00edna codificada por el gen NUCB2 y que, recientemente, se ha asociado con la s\u00edntesis y la regulaci\u00f3n de la insulina, la homeostasis de la glucosa y su posible participaci\u00f3n en la etiopatogenia de la diabetes mellitus de tipo 2. Objetivo. Analizar la relaci\u00f3n entre los niveles s\u00e9ricos de nesfatina-1 y la diabetes mellitus de tipo 2.Materiales y m\u00e9todos. Se incluyeron art\u00edculos de las plataformas PubMed, Scopus y DOAJ, publicados entre el 2012 y el 2024. Las palabras clave de la b\u00fasqueda fueron \u201cdiabetes mellitus\u201d, \u201cdiabetes\u201d, \u201cdiabetes mellitus tipo 2\u201d, \u201cnesfatin-1\u201d, \u201cNUCB2\u201d, \u201cELISA\u201d, \u201cplasma\u201d y \u201csuero\u201d. Se eligieron estudios de casos y controles y de dise\u00f1o transversal realizados en humanos, que tuvieran acceso al texto completo y contaran con la cuantificaci\u00f3n de nesfatina-1.Resultados. Para el an\u00e1lisis estad\u00edstico, se incluyeron ocho art\u00edculos con un total de 305 pacientes con diabetes mellitus de tipo 2 y 205 controles. Los resultados mostraron una relaci\u00f3n significativa entre los valores de nesfatina-1 y el desarrollo de diabetes mellitus de tipo 2, con un alto \u00edndice de heterogeneidad entre los estudios (t2 = 3,91; \u03c72 = 349,63, p &lt;0,00001; I2 = 98 %).Conclusiones. Los resultados muestran una relaci\u00f3n significativa entre las concentraciones de nesfatina-1 y la diabetes mellitus de tipo 2, lo que respalda su utilidad como biomarcador de esta enfermedad.<\/jats:p>","DOI":"10.7705\/biomedica.7708","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T18:50:07Z","timestamp":1755283807000},"page":"436-445","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Metan\u00e1lisis sobre los niveles s\u00e9ricos de nesfatina-1 en la diabetes mellitus de tipo 2","A meta-analysis about the relationship of serum nesfatin-1 levels in patients with type 2 diabetes mellitus"],"prefix":"10.7705","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6575-9587","authenticated-orcid":false,"given":"Elizabeth","family":"Reyes-Luc\u00eda","sequence":"first","affiliation":[{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"},{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7673-724X","authenticated-orcid":false,"given":"Ang\u00e9lica","family":"Ram\u00edrez-Guerrero","sequence":"additional","affiliation":[{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"},{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-2339","authenticated-orcid":false,"given":"Christian","family":"Gonz\u00e1lez-Villase\u00f1or","sequence":"additional","affiliation":[{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0878-2401","authenticated-orcid":false,"given":"Nelly","family":"Mac\u00edas-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Laboratorio de Gen\u00e9tica Humana, Centro Universitario del Sur, Ciudad Guzm\u00e1n, Jalisco, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"151007","unstructured":"1. World Health Organization. Diabetes. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/diabetes"},{"key":"151008","unstructured":"2. International Diabetes Federation. IDF Diabetes Atlas. 10th edition. Bruselas: Edition Committee; 2024. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf"},{"key":"151009","unstructured":"3. National Institute of Diabetes and Digestive and Kidney Diseases. Risk factors for type 2 diabetes. Washington: NIDKK; 2022. Fecha de consulta: 3 de mayo de 2024. Disponible en: https:\/\/www.niddk.nih.gov\/health-information\/diabetes\/overview\/risk-factors-type-2-diabetes"},{"key":"151010","unstructured":"4. Petrie JR, Boyle JG. Diabetes mellitus. In: Davidson\u2019s Principles and Practice of Medicine. 24th edition. London: Elsevier; 2023. p. 703-53. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/www.clinicalkey.es\/!\/content\/book\/3-s2.0-B9780702083471000211?scrollTo=%23hl0003261"},{"key":"151011","unstructured":"5. Asociaci\u00f3n Latinoamericana de Diabetes. Gu\u00edas ALAD sobre el diagn\u00f3stico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia. 9a edici\u00f3n. M\u00e9xico: Rev ALAD; 2019. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/www.revistaalad.com\/guias\/5600AX191_guias_alad_2019.pdf"},{"key":"151012","doi-asserted-by":"crossref","unstructured":"6. Pa\u0142asz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R, et al. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides. 2012;46:105-12. https:\/\/doi.org\/10.1016\/j.npep.2011.12.002","DOI":"10.1016\/j.npep.2011.12.002"},{"key":"151013","doi-asserted-by":"crossref","unstructured":"7. Luo JJ, Wen FJ, Qiu D, Wang SZ. Nesfatin-1 in lipid metabolism and lipid-related diseases. Clin Chim Acta. 2021;522:23-30. https:\/\/doi.org\/10.1016\/j.cca.2021.08.005","DOI":"10.1016\/j.cca.2021.08.005"},{"key":"151014","doi-asserted-by":"crossref","unstructured":"8. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of Nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443:709-12. https:\/\/doi.org\/10.1038\/nature05162","DOI":"10.1038\/nature05162"},{"key":"151015","doi-asserted-by":"crossref","unstructured":"9. Dore R, Krotenko R, Reising JP, Murru L, Sundaram SM, Di Spiezio A, et al. Nesfatin-1 decreases the motivational and rewarding value of food. Neuropsychopharmacology. 2020;45:1645-55. https:\/\/doi.org\/10.1038\/s41386-020-0682-3","DOI":"10.1038\/s41386-020-0682-3"},{"key":"151016","doi-asserted-by":"crossref","unstructured":"10. Chen X, Dong J, Jiao Q, Du X, Bi M, Jiang H. \u201cSibling\u201d battle or harmony: Crosstalk between nesfatin-1 and ghrelin. Cell Mol Life Scis. 2022;79:169. https:\/\/doi.org\/10.1007\/s00018-022-04193-6","DOI":"10.1007\/s00018-022-04193-6"},{"key":"151017","doi-asserted-by":"crossref","unstructured":"11. Shimizu H, Oh IS, Okada S, Mori M. Nesfatin-1: An overview and future clinical application. Endocr J. 2009;56:537-43. https:\/\/doi.org\/10.1507\/endocrj.k09e-117","DOI":"10.1507\/endocrj.K09E-117"},{"key":"151018","doi-asserted-by":"crossref","unstructured":"12. Xu Y, Chen F. Antioxidant, anti-inflammatory, and anti-apoptotic activities of nesfatin-1: A review. J Inflamm Res. 2020:13:607-17. https:\/\/doi.org\/10.2147\/JIR.S273446","DOI":"10.2147\/JIR.S273446"},{"key":"151019","doi-asserted-by":"crossref","unstructured":"13. Gharanei S, Ramanjaneya M, Patel AH, Patel V, Shabir K, Auld C, et al. NUCB2\/nesfatin-1 reduces obesogenic diet induced inflammation in mice subcutaneous white adipose tissue. Nutrients. 2022;14:1409. https:\/\/doi.org\/10.3390\/nu14071409","DOI":"10.3390\/nu14071409"},{"key":"151020","doi-asserted-by":"crossref","unstructured":"14. L\u00f3pez-G\u00f3mez A, Mart\u00ednez-Cordero C. Nesfatina-1: una nueva hormona anorexig\u00e9nica. Hosp Med Clin Manag. 2018;11:130-6.","DOI":"10.24875\/HMCM.18000095"},{"key":"151021","doi-asserted-by":"crossref","unstructured":"15. Kadim BM, Hassan EA. Nesfatin-1 as a diagnosis regulatory peptide in type 2 diabetes mellitus. J Diabetes Metab Disord. 2022;21:1369-75. https:\/\/doi.org\/10.1007\/s40200-022-01070-8","DOI":"10.1007\/s40200-022-01070-8"},{"key":"151022","doi-asserted-by":"crossref","unstructured":"16. Algul S, Ozkan Y, Ozcelik O. Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiol Res. 2016;65:979-85. https:\/\/doi.org\/10.33549\/physiolres.933186","DOI":"10.33549\/physiolres.933186"},{"key":"151023","doi-asserted-by":"crossref","unstructured":"17. Li XS, Yan CY, Fan YJ, Yang JL, Zhao SX. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Ann Transl Med. 2020;8:290. https:\/\/doi.org\/10.21037\/atm.2020.03.02","DOI":"10.21037\/atm.2020.03.02"},{"key":"151024","doi-asserted-by":"crossref","unstructured":"18. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159:72-7. https:\/\/doi.org\/10.1016\/j.regpep.2009.11.003","DOI":"10.1016\/j.regpep.2009.11.003"},{"key":"151025","doi-asserted-by":"crossref","unstructured":"19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74:790-9. https:\/\/doi.org\/10.1016\/j.rec.2021.07.010","DOI":"10.1016\/j.rec.2021.07.010"},{"key":"151026","unstructured":"20. Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. La Escala Newcastle-Ottawa (NOS) para evaluar la calidad de estudios no aleatorios en metan\u00e1lisis. Ottawa: Ottawa Hospital Research Institute; 2021."},{"key":"151027","unstructured":"21. Rostom A, Dub\u00e9 C, Cranney A, Saloojee N, Garritty C, Sampson M, et al. Appendix D: Quality assessment forms. In: Cochrane handbook for systematic reviews of interventions. Rockville (MD): Agency for Healthcare Research and Quality; 2004. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK35156\/"},{"key":"151028","unstructured":"22. Review Manager (RevMan) [software]. Version 5.3. Copenhaguen: The Nordic Cochrane Center, The Cochrane Collaboration; 2020. Fecha de consulta: 2 de mayo de 2024. Disponible en: https:\/\/revman.cochrane.org"},{"key":"151029","unstructured":"23. Epidat: programa para an\u00e1lisis epidemiol\u00f3gico de datos, Versi\u00f3n 3.1. [software]. Santiago de Compostela (ES): Conseller\u00eda de Sanidade, Xunta de Galicia; 2006. Fecha de consulta: 13 de mayo de 2024. Disponible en: https:\/\/www.sergas.es\/Saude-publica\/EPIDAT-3-1?idioma=es"},{"key":"151030","unstructured":"24. Tamayo y Orozco JA, Lastiri-Quir\u00f3s HS. La enfermedad renal cr\u00f3nica en M\u00e9xico. Hacia una pol\u00edtica nacional para enfrentarla. M\u00e9xico: Academia Nacional de Medicina de M\u00e9xico; 2016. Fecha de consulta: 13 de mayo de 2024. Disponible en: https:\/\/www.anmm.org.mx\/publicaciones\/ultimas_publicaciones\/ENF-RENAL.pdf"},{"key":"151031","doi-asserted-by":"crossref","unstructured":"25. Mart\u00ednez-Escalante JE, Romero-Ibarg\u00fcengoitia ME, Plata-\u00c1lvarez H, L\u00f3pez-Betancourt G, Otero-Rodr\u00edguez R, Garza-Cant\u00fa A, et al. Pie diab\u00e9tico en M\u00e9xico: factores de riesgo para mortalidad posterior a una amputaci\u00f3n mayor, a 5 a\u00f1os, en un hospital de salud p\u00fablica de segundo nivel. Cir Cir. 2021;89:284-90. https:\/\/doi.org\/10.24875\/CIRU.20000209","DOI":"10.24875\/CIRU.20000209"},{"key":"151032","unstructured":"26. Instituto Nacional de Estad\u00edstica y Geograf\u00eda. Estad\u00edsticas a prop\u00f3sito del d\u00eda mundial de la diabetes (14 de noviembre). M\u00e9xico: INE; 2021. Fecha de consulta: 13 de mayo de 2024. Disponible en: https:\/\/www.inegi.org.mx\/contenidos\/saladeprensa\/aproposito\/2021\/EAP_Diabetes2021.pdf"},{"key":"151033","doi-asserted-by":"crossref","unstructured":"27. Mirakhor-Samani S, Ghasemi H, Rezaei-Bookani K, Shokouhi B. Serum nesfatin-1 level in healthy subjects with weight-related abnormalities and newly diagnosed patients with type 2 diabetes mellitus: A case-control study. Acta Endocrinol (Buchar). 2019;5:69-73. https:\/\/doi.org\/10.4183\/aeb.2019.69","DOI":"10.4183\/aeb.2019.69"},{"key":"151034","doi-asserted-by":"crossref","unstructured":"28. Matta RA, El-Hini SH, Eldin Salama AM, Moaness HM. Serum nesfatin-1 is a biomarker of pre-diabetes and interplays with cardiovascular risk factors. Egypt J Intern Med. 2022;34:15. https:\/\/doi.org\/10.1186\/s43162-022-00106-y","DOI":"10.1186\/s43162-022-00106-y"},{"key":"151035","doi-asserted-by":"crossref","unstructured":"29. Khalil UA, Mohamed OE, Abdullah AA, Fawzy MS, Rashad NM, Samir GM. Do serum nesfatin-1 levels have a predictive role in type-2 diabetes mellitus and its microvascular complications? A case-control study. Cureus. 2024;16:e53007. https:\/\/doi.org\/10.7759\/cureus.53007","DOI":"10.7759\/cureus.53007"},{"key":"151036","doi-asserted-by":"crossref","unstructured":"30. Huang K, Liang Y, Wang K, Wu J, Luo H, Yi, B. Influence of circulating nesfatin-1, GSH, and SOD on insulin secretion in the development of T2DM. Front Public Health. 2022;10:882686. https:\/\/doi.org\/10.3389\/fpubh.2022.882686","DOI":"10.3389\/fpubh.2022.882686"},{"key":"151037","doi-asserted-by":"crossref","unstructured":"31. Abed BA, Farhan LO, Dawood AS. Relationship between serum nesfatin-1, adiponectin, resistin concentration, and obesity with type 2 diabetes mellitus. Baghdad Sci J. 2023;21:0117. https:\/\/doi.org\/10.21123\/bsj.2023.8119","DOI":"10.21123\/bsj.2023.8119"},{"key":"151038","doi-asserted-by":"crossref","unstructured":"32. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:91-5. https:\/\/doi.org\/10.1055\/s-0031-1286339","DOI":"10.1055\/s-0031-1286339"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7708\/5752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7708\/5863","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7708\/5752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:45:29Z","timestamp":1773265529000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/7708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,11]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.7708","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"2025-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Art\u00edculos originales","name":"content_type","label":"Content Type"}]}}